1.Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modeling. Med Decis Making. 2004; 24: 207–227.
2.American Heart Association. Heart disease and stroke statistics – 2006 Update. Dallas, TX: American Heart Association; 2006.
4.Anon. Special Report: Cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure. Technol Eval Cent Asses Program Exec Summ. 2004; 19: 1.
5.Brown A, Young T, Meenan B. Medical device prices follow the experimental curve. J Med Marketing. In press.
6.Claxton K, Lacey LF, Walker SG. Selecting treatments: A decision theoretic approach. J R Stat Soc Ser A Stat Soc. 2000; 163: 211–225.
7.Claxton K. The irrelevance of inference: A decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999; 18: 341–364.
8.Claxton K, Ginnelly L, Sculpher M et al. , A pilot study on the use of decision theory and value of information analysis as part of the NHS health technology assessment programme. Health Technol Assess. 2004; 8: 1–103, iii.
9.Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 1996; 5: 513–524.
10.Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet. 2002; 360: 711–715.
11.Clegg AJ, Scott DA, Loveman E et al. , The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: A systematic review and economic evaluation. Health Technol Assess. 2005; 9: 1–148.
12.Cleland JG. Heart failure: A medical hydra. Lancet. 1998; 352 (Suppl 1): SI1–SI2.
13.Day GS, Montgomery DB. Diagnosing the experience curve. J Mark. 1983; 47: 44–58.
14.Derose J, Jarvik R. Axial flow pumps. In: Goldstein DJOz MC, eds. Cardiac assist devices. New York: Futura Publishing; 359–374. 2000:
15.Dominguez LJ, Parrinello G, Amato P et al. , Trends of congestive heart failure epidemiology: Contrast with clinical trial results. Cardiologia. 1999; 44: 801–808.
16.Evans RW. Cardiac replacement: Estimation of need, demand and supply. In: Rose EAStevenson LW, eds. Management of end-stage heart disease. Philadelphia PA: Lippincott-Raven; 1998: 13–24.
18.Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making. 1998; 18: 95–109.
19.Fenwick E, Claxton K, Sculpher M et al. , Improving the efficiency and relevance of health technology assessment: The role of iterative decision analytic modelling. Report No. Discussion Paper 179. York: Centre for Health Economics; 2000.
20.Fisher DC, Lake KD, Reutzel TJ et al. , Changes in health-related quality of life and depression in heart transplant recipients. J Heart Lung Transplant. 1995; 14: 373–381.
21.Garthwaite PH, Kadane JB, O'Hagan A. Statistical methods for eliciting probability distributions. J Am Stat Assoc. 2005; 100: 680–700.
22.Henderson BD. The application and misapplication of the experience curve. J Bus Strategy. 1984; 4: 3–9.
23.HM Treasury. The green book: Appraisal and evaluation in central government. London: HMT; 2003.
24.Hoshi H, Shinshi T, Takatani S. Third-generation blood pumps with mechanical noncontact magnetic bearings. Artif Organs. 2006; 30: 324–338.
25.Hussey JC, Bond ZC, Collett D et al. , 2004. on behalf of UK Transplant Cardiothoracic Advisory Group. Long-term patient survival for heart transplant recipients in the UK.
26.John R. Donor management and selection for heart transplantation. Semin Thorac Cardiovasc Surg. 2004; 16: 364–369.
27.Kirklin JK, Holman WL. Mechanical circulatory support therapy as a bridge to transplant or recovery (new advances). Curr Opin Cardiol. 2006; 21: 120–126.
28.Lietz K, Miller LW. Will left-ventricular assist device therapy replace heart transplantation in the foreseeable future? Curr Opin Cardiol. 2005; 20: 132–137.
29.Lilford RJ, Braunholtz D. The statistical basis of public policy: A paradigm shift is overdue. BMJ. 1996; 313: 603–607.
30.Long JW, Kfoury AG, Slaughter MS et al. , Long-term destination therapy with the HeartMate XVE left ventricular assist device. Improved outcomes since the REMATCH Study. Congest Heart Fail. 2005; 11: 133–138.
31.Miller LW, Nelson KE, Bostic RR et al. , Hospital costs for left ventricular assist devices for destination therapy: Lower costs for implantation in the post-REMATCH era. J Heart Lung Transplant. 2006; 25: 778–784.
32.Morris PA. Decision analysis expert use. Manage Sci. 1974; 20: 1233–1241.
33.Moskowitz AJ, Weinberg AD, Oz MC et al. , Quality of life with an implanted left ventricular assist device. Ann Thorac Surg. 1997; 64: 1764–1769.
34.Noon GP, Morley D, Irwin S et al. , The DeBakey ventricular assist device. In: Goldstein DJ, Oz MC eds. Cardiac assist devices. New York: Futura Publishing; 2000:375–386.
35.Oz MC, Gelijns AC, Miller L et al. , Left ventricular assist devices as permanent heart failure therapy: The price of progress. Ann Surg. 2003; 238: 577–583.
36.Park SJ, Tector A, Piccioni W et al. , Left ventricular assist devices as destination therapy: A new look at survival. J Thorac Cardiovasc Surg. 2005; 129: 9–17.
37.Philbin EF. Comprehensive multidisciplinary programs for the management of patients with congestive heart failure. J Gen Intern Med. 1999; 14: 130–135.
38.Raiffa H, Schlaifer R. Applied statistical decision theory. Boston: Harvard University, Graduate School of Business Administration; 1961.
39.Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ. 2004; 329: 224–227.
40.Richards PS, Nelson KA, Frazier OH et al. , Why referred potential heart donors aren't used. Tex Heart Inst J. 1993; 20: 218–222.
41.Rose EA, Moskowitz AJ, Packer M et al. , The REMATCH Trial: Rationale, design, and end points. randomized evaluation of mechanical assistance for the treatment of congestive heart failure. Ann Thorac Surg. 1999; 67: 723–730.
42.Rose EA, Gelijns AC, Moskowitz AJ; and the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001; 345: 1435–1443.
43.Savage LJ. The foundations of statistics. New York: John Wiley; 1954.
44.Siegenthaler MP, Westaby S, Frazier OH et al. , Advanced heart failure: Feasibility study of long-term continuous axial flow pump support. Eur Heart J. 2005; 26: 1031–1038.
45.Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. New York: Wiley; 2004.
46.Stevenson LW, Shekar P. Ventricular assist devices for durable support. Circulation. 2005; 112: e111–e115.
47.Takatani S. Progress of rotary blood pumps. Artif Organs. 2006; 30: 317–321.
48.Tsukui H, Winowich S, Stanford E et al. , Does a rotary pump provide full cardiac decompression and circulatory support?— from clinical experiences of HeartMate II with severe congestive heart failure patients. ASAIO. 2005; 51: 2.
49.Willan AR, Pinto EM. The value of information and optimal clinical trial design. Stat Med. 2005; 24: 1791–1806.
50.Zaman SN. Managing elderly patients with end-stage heart failure. CME J Geriatr Med. 2001; 3: 105–109.